安徽医学
安徽醫學
안휘의학
ANHUI MEDICAL JOURNAL
2009年
7期
740-742
,共3页
非小细胞肺癌%多西紫杉醇%易瑞沙%二线治疗
非小細胞肺癌%多西紫杉醇%易瑞沙%二線治療
비소세포폐암%다서자삼순%역서사%이선치료
Non-small cell lung cancer%Docetaxel%Iressa%Second-line chemotherapy
目的 明确易瑞沙二线治疗晚期非小细胞肺癌(NSCLC)的疗效及毒副反应.方法 50例经组织学或细胞学检查确诊的ⅢB或Ⅳ期NSCLC患者,随机分为两组,分别接受易瑞沙250 mg/d,口服,或多西紫杉醇75 mg/m2,第1天,静脉滴注,顺铂75 mg/m2,静脉滴注,第1天,每21天为1个周期.结果 两组均无CR,多西紫杉醇组(A组)和易瑞沙组(B组)总有效率分别为24%和32%,1年生存率分别为32%和40%,两组差异无统计学意义(P=0.529,P=0.556).易瑞沙治疗组副反应以轻度皮疹和腹泻为主,多西紫杉醇组主要为消化道反应、骨髓抑制、脱发等,耐受性方面,易瑞沙具有明显优势.结论 易瑞沙和多西紫杉醇联合顺铂3周方案二线治疗NSCLC相比,疗效相似,但毒性明显下降,耐受性好.
目的 明確易瑞沙二線治療晚期非小細胞肺癌(NSCLC)的療效及毒副反應.方法 50例經組織學或細胞學檢查確診的ⅢB或Ⅳ期NSCLC患者,隨機分為兩組,分彆接受易瑞沙250 mg/d,口服,或多西紫杉醇75 mg/m2,第1天,靜脈滴註,順鉑75 mg/m2,靜脈滴註,第1天,每21天為1箇週期.結果 兩組均無CR,多西紫杉醇組(A組)和易瑞沙組(B組)總有效率分彆為24%和32%,1年生存率分彆為32%和40%,兩組差異無統計學意義(P=0.529,P=0.556).易瑞沙治療組副反應以輕度皮疹和腹瀉為主,多西紫杉醇組主要為消化道反應、骨髓抑製、脫髮等,耐受性方麵,易瑞沙具有明顯優勢.結論 易瑞沙和多西紫杉醇聯閤順鉑3週方案二線治療NSCLC相比,療效相似,但毒性明顯下降,耐受性好.
목적 명학역서사이선치료만기비소세포폐암(NSCLC)적료효급독부반응.방법 50례경조직학혹세포학검사학진적ⅢB혹Ⅳ기NSCLC환자,수궤분위량조,분별접수역서사250 mg/d,구복,혹다서자삼순75 mg/m2,제1천,정맥적주,순박75 mg/m2,정맥적주,제1천,매21천위1개주기.결과 량조균무CR,다서자삼순조(A조)화역서사조(B조)총유효솔분별위24%화32%,1년생존솔분별위32%화40%,량조차이무통계학의의(P=0.529,P=0.556).역서사치료조부반응이경도피진화복사위주,다서자삼순조주요위소화도반응、골수억제、탈발등,내수성방면,역서사구유명현우세.결론 역서사화다서자삼순연합순박3주방안이선치료NSCLC상비,료효상사,단독성명현하강,내수성호.
Objective To evaluate the antitumor efficiency and toxicity of Iressa in advanced non-small-cell lung cancer (NSCLC). Methods 50 patients with stage Ⅲ B or ⅣV NSCLC (proved by histology or cytology) were randomly divided into two groups.Patients received oral Iressa 250 mg/day or docetaxel 75 mg/m2 ,ivgtt dayl ,cisplatin 75 mg/m2 ,ivgtt day 1 ,repeated every 21 days. Results There was no CR in beth groups. The overall response rate was 24% and 32% in docetaxel group(A) and lressa group(B). The one-year survival rate was 32% and 40% respectively. There were no significant difference for twogroups(P=0.529 ,P =0. 556). The most common adverse effects of Iressa were skin reactions and diarrhea which were generally mild. The main side effects of docetaxel group were gastrointestinal reactions,myelosuppression,alopecia et. Iressa had obvious advantages in tolerance. Conclusion In comparison with the 3 -weeks'dtocetaxel/cisplatin chemotherapy, Iressa had similar response rate with lower toxicitiesand better tolerated.
